Matthias Hofer
Matthias is a Senior Principal Economist at OHE. His expertise lies at the intersection of regulatory science, health economics, and policy. His research explores the societal and patient value of health technologies, the dynamics of pharmaceutical markets and innovation, and the economic impact of policy and technological change.
Before joining OHE, Matthias worked at Imperial College Business School conducting research into the industrial organisation, manufacturing capabilities, productivity, and competitiveness of the UK pharmaceutical sectors. He has also worked at the European Medicines Agency and UK Research and Innovation, where he was involved in the incentivisation, regulation, and appraisal of pharmaceutical innovation for rare diseases, children, and COVID-19.
Matthias holds an MSc in Biomedicine and Biotechnology from the University of Veterinary Medicine Vienna, a PhD in Clinical Neuroscience from the University of Cambridge, and an MSc in Health Policy from Imperial College London.
Publications and Insights
- Insight: The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
- Publication: Understanding the Full Value of Long-Acting Therapies: less is more?
- Publication: The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region
- Insight: Advancing Rare Disease Care: Challenges and Key Issues
- Publication: The Importance of Diversity of Supply in Rare Diseases Markets
- Publication: A Spotlight on Haemophilia Therapies
- Insight: Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
- Insight: OHE’s AMR consultation response
- Publication: Innovation for Health System Efficiency and Improvement
- Publication: Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
- Publication: Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective